ALT - Altimmune Inc Stock Price, Fair Value and News

$8.25+0.07 (+0.86%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

ALT Price Action

Last 7 days

-8.6%

Last 30 days

2.5%

Last 90 days

5.9%

Trailing 12 Months

4.6%

ALT RSI Chart

ALT Valuation

Market Cap

586.8M

Price/Earnings (Trailing)

-5.67

Price/Sales (Trailing)

1.6K

EV/EBITDA

-6.62

Price/Free Cashflow

-7.51

ALT Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ALT Fundamentals

ALT Revenue

Revenue (TTM)

426.0K

Rev. Growth (Yr)

-98.62%

ALT Earnings

Earnings (TTM)

-103.5M

Earnings Growth (Yr)

-10.52%

Earnings Growth (Qtr)

7.28%

ALT Profitability

EBT Margin

-22930.75%

Return on Equity

-77.61%

Return on Assets

-70.01%

Free Cashflow Yield

-13.31%

ALT Investor Care

Shares Dilution (1Y)

32.38%

Diluted EPS (TTM)

-1.56

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	911.6K	37.0K	391.0K	426.0K
2022	3.5M	2.7M	1.8M	0
2021	6.8M	6.2M	3.4M	4.4M
2020	5.1M	4.2M	6.4M	8.2M
2019	10.6M	9.8M	7.8M	5.8M
2018	13.1M	12.5M	10.6M	10.3M
2017	3.1M	5.4M	9.0M	10.7M
2016	4.6M	4.2M	3.9M	3.8M
2015	13.5M	11.0M	11.2M	10.6M
2014	15.2M	14.5M	12.0M	10.2M
2013	25.5M	23.5M	20.3M	17.9M
2012	24.1M	24.0M	25.4M	25.2M
2011	21.8M	22.6M	23.4M	24.3M
2010	0	0	0	21.0M

Get all data in R, Python etc through our Historical Stock Data APIs

About Altimmune Inc

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

CEO	Dr. Vipin K. Garg Ph.D.
WEBSITE	https://altimmune.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	52

Altimmune Inc Frequently Asked Questions

What is the ticker symbol for Altimmune Inc? What does ALT stand for in stocks?

ALT is the stock ticker symbol of Altimmune Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Altimmune Inc (ALT)?

As of Fri Dec 20 2024, market cap of Altimmune Inc is 586.78 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ALT stock?

You can check ALT's fair value in chart for subscribers.

Is Altimmune Inc a good stock to buy?

The fair value guage provides a quick view whether ALT is over valued or under valued. Whether Altimmune Inc is cheap or expensive depends on the assumptions which impact Altimmune Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ALT.

What is Altimmune Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, ALT's PE ratio (Price to Earnings) is -5.67 and Price to Sales (PS) ratio is 1.58 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ALT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Altimmune Inc's stock?

In the past 10 years, Altimmune Inc has provided -0.215 (multiply by 100 for percentage) rate of return.